Kyverna Therapeutics, Inc.

JPMorgan maintained an Overweight rating with a $29 price target even after trimming it by $1, implying over 237% upside from the ~$8.60 trading price. The consensus average target of $30 across five buy-rated analysts signals strong institutional conviction in Kyverna's long-term value.

Despite a lofty consensus price target of $30, the stock trades near $9.91 and the company continues to post losses, with a forecasted EPS of -2.78 for the current year. Weiss Ratings and Wall Street Zen both issued sell ratings, questioning whether the optimistic targets are grounded in near-term fundamentals.

KYTX surged over 188% in the last 52 weeks and was recently added to the Russell 2000 and Russell 3000 index families, creating a passive fund buying floor. The strong price momentum reflects growing investor confidence in Kyverna's pipeline and commercial potential.

Despite impressive price gains, Kyverna's Piotroski F-Score sits at just 1 out of 9 — a signal of very weak financial health. The company posts no dividends, no near-term revenue growth forecast, and a projected 5-year EPS decline of -12.68%, raising concerns about long-term sustainability.

Kyverna Therapeutics raised $319 million in its February IPO launch, a strong signal of market confidence in its cell therapy platform. HC Wainwright reissued a buy rating with a $25 price target as recently as June, suggesting analysts see meaningful clinical and commercial milestones ahead.

Early commercial reception has been uneven, with responses to data readouts described as inconsistent and accompanied by dire warnings about lack of market appetite. A -13% single-day selloff following a minor JPMorgan price target trim highlights extreme stock fragility and investor skepticism about execution.